# Phase II Iressa & Carbo/Gem in NSCLC

> **NCT00264498** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 38 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00264498
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2008-06
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2009-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00264498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00264498, "Phase II Iressa & Carbo/Gem in NSCLC". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00264498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*